pipette
ESEspañol

LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease

S. Zanin, F. Lager, M. Simon-Sola, C. Gaborit, G. Renault, F. Mingozzi, A. Rotig, M. Cavazzana, M. Metodiev, B. Ruzzenente

PreprintClaims a big stepReal-world use

In the authors' words

Pathogenic variants in LRPPRC disrupt mitochondrial gene expression, causing severe and incurable mitochondrial disease with neurological involvement accompanied by hepatopathy or cardiomyopathy. The development for gene therapy for LRPPRC-linked disease is hindered by the large LRPPRC coding sequence exceeding AAV cargo capacity when combined with classical regulatory elements. Here, we engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to heart and skeletal muscle-specific Lrpprc knockout mice. This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival. While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction. These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.

Main resultLimitation the authors admit

In plain words AI summary

Mutations in the LRPPRC gene cause severe mitochondrial disease affecting the brain, liver, or heart. The researchers engineered compact gene therapy vectors to deliver working copies of LRPPRC to mice lacking this gene. The treatment restored gene expression in the heart, preserved energy production, prevented heart disease, and greatly extended survival. Muscle repair was incomplete, but the therapy successfully stopped fatal heart failure. This study provides the first evidence that LRPPRC gene replacement could treat this form of mitochondrial disease.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Saturday, November 14. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.12.762002